Subject to the requirements of this [Article 12, CytomX]X] will have the sole right to publish and make scientific presentations, issue press releases (except with respect to the terms of this Agreement, which is governed by [Section 12.2]) or make other public disclosures with respect to ​ consistent with CytomX’s publication practices. Regeneron will not issue any such publications related to the ​ without CytomX’s prior written consent, except as required by applicable Law. Notwithstanding the foregoing, any such publication or presentation to be made by CytomX that names Regeneron will require the prior written consent of Regeneron.

Subject to the requirements of this [Article 12], Regeneron will have the sole right to publish and make scientific presentations, issue press releases (except with respect to the terms of this Agreement, which is governed by [Section 12.2]) or make other public disclosures with respect to ​ consistent with Regeneron’s publication policy. CytomX will not issue any such publications related to the ​ without Regeneron’s prior written consent, except as required by applicable Law or as otherwise permitted under this Agreement. Notwithstanding the foregoing, any such publication or presentation to be made by Regeneron that names CytomX will require the prior written consent of CytomX.